Curaleaf Q1 2023 Financials: Higher Revenue, Lower Margins, Wider Losses

Curaleaf Holdings (CSE: CURA) reported its Q1 2023 financials late last night, just days after publishing the results of the previous quarter. The cannabis firm posted $336.5 million in revenues, a sequential decline from Q4 2022’s $344.9 million but a 14% jump from Q1 2022’s $296.1 million.

The company said its year-over-year revenue growth is primarily driven by new retail store openings and a significant focus on research and development, which has resulted in the introduction of 171 products in 2022, three new brand launches, and contributions from Tryke and Four 20 Pharma.

“2023 is off to a strong start for Curaleaf, with first quarter year-over-year revenue growing 14% to $336.5 million, beating our guidance of low double-digit growth,” said Executive Chairman Boris Jordan. “Adjusted gross margin was 48% and adjusted EBITDA margin was 22%.”

Gross margin for the quarter came in at 47.8%, down from last year’s 54.5%, mainly due to higher sales costs. Operating margin also dwindled down to 4.9% from 8.9% in the year-ago period.

Net loss for the quarter ended at $56.5 million, $10.1 million of which came from discontinued operations. This is a wider loss from last year’s $38.3 million net loss, when $4.3 million coming from discontinued operations.

The bottomline figure translates to a $0.07 loss per share.

Calibrating for financial items, adjusted EBITDA came in at $73.2 million for the quarter, down from both last quarter’s $76.9 million and last year’s $76.1 million.

The firm generated operating cash of $14.2 million, leading to end with a cash balance of $115.8 million, down from its balance of $163.2 million at the end of the last quarter. Total current assets came in at $599.4 million while total current liabilities came in at $544.7 million.

Curaleaf announced a single-day sales record on April 20, an unofficial holiday for marijuana users, propelled by sales in New Jersey, which increased 77% year over year.

Curaleaf last traded at $3.70 on the CSE, up 7.6% on the day. The stock is down more than 32% year to date.


Information for this story was found via Sedar and the sources mentioned. The author has no securities or affiliations related to this organization. Views expressed within are solely that of the author. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

When 4% of Global Copper Disappears Overnight | David Gower – Emerita Resources

Mining M&A: Gold X2 Acquires Kesselrun Resources

They Said Oil Was Dead. They Were Wrong. | Michael Judson – Record Resources

Recommended

Military Seizes Power in Madagascar After President Flees

Altamira Gold Hits 395.5 Metres Of 0.4 g/t Gold At Maria Bonita

Related News

Week Ahead: U.S Cannabis Earnings Expectations For CRON, CURA, IIPR And More

Cannabis investors are facing a harsh 2023 as shares of the largest U.S cannabis companies...

Sunday, February 26, 2023, 01:28:00 PM

Curaleaf To Exit Most Operations In California, Oregon And Colorado Immediately

The protracted bear market in the cannabis sector is beginning to impact tier one operations,...

Thursday, January 26, 2023, 08:52:53 AM

Curaleaf Sees Consensus Estimates Stay Flat After Q1 Results

Curaleaf Holdings (CSE: CURA) reported its first-quarter results on May 10th, beating the consensus estimates...

Saturday, May 15, 2021, 04:24:00 PM

Curaleaf Amends Terms of Grassroots Acquisition

Nearly a year after the initial announcement, Curaleaf Holdings (CSE: CURA) this morning announced that...

Monday, June 22, 2020, 12:13:11 PM

Curaleaf Sees New Jersey Deny Renewal Of Adult Use License

Curaleaf (CSE: CURA) is reeling this morning after a decision by New Jersey’s Cannabis Regulator...

Friday, April 14, 2023, 08:11:39 AM